What does the research say about stem cell therapy?
A review of registered trials and preclinical studies on stem cell therapy, covering mesenchymal stem cells, gene-modified hematopoietic stem cells, and other approaches in liver failure, beta-thalassemia, osteoarthritis
Stem cell therapy is a broad term for the administration of stem cells or their derivatives to treat disease. The cells most often studied are mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and induced pluripotent stem cells (iPSCs). These cells are defined by their capacity for self-renewal and differentiation into multiple lineages. No single molecular formula or sequence applies to all stem cell therapies; each product is a living cell population with its own characteristics. The research centres on several pathways and receptor families, including the mitochondrial oxidative phosphorylation (OXPHOS) pathway that regulates MSC fate [5], and the hematopoietic stem cell compartment that gives rise to all blood lineages [2].
Clinical translation remains at an early stage. As of 2025, most stem cell therapies are experimental, with only a small number approved for specific indications. The evidence base includes registered clinical trials and preclinical animal studies, which are summarised below.
Research Studies
Mesenchymal stem cells and non-viral acute-on-chronic liver failure
A Phase II trial is evaluating MSC therapy in patients with non-viral acute-on-chronic liver failure (ACLF) in India [1]. The study aims to develop and validate MSC-based therapy to promote native liver regeneration and offer a transplant-free treatment option. The rationale includes the rising burden of liver disease and the scarcity of donor organs: over 100,000 liver transplants are needed annually in India, but only about 2,500 are performed [1]. The trial is ongoing and results are not yet available.
Gene-modified hematopoietic stem cells and transfusion-dependent beta-thalassemia
A Phase IIb trial is testing autologous hematopoietic stem and progenitor cells (HSPCs) genetically modified with the GLOBE lentiviral vector in patients with transfusion-dependent beta-thalassemia [2]. The study is a single-arm, open-label trial that will enrol 9 patients and administer a single infusion of the modified cells using an improved transduction protocol [2]. The goal is to restore functional beta-globin production. This approach is ex vivo, meaning the patient's own cells are collected, modified in the laboratory, and then returned. The trial is ongoing.
Stem cell therapy and knee osteoarthritis
Stem cell therapy is among the regenerative technologies being explored for knee osteoarthritis (OA), a degenerative joint disease with a prevalence exceeding 40% in the elderly [3]. Current treatments are limited to symptom management, and no cure exists [3]. A clinical trial is investigating the effect of pulsed electromagnetic field (PEMF) therapy in patients with knee OA, with a focus on cost-effectiveness and side effects [3]. While this trial does not directly test stem cells, it reflects the broader search for affordable regenerative options. Stem cell approaches for OA remain experimental.
Autologous mesenchymal stem cells and premature ovarian failure
A study is evaluating the therapeutic potential of autologous MSC therapy in women with premature ovarian failure (POF) [4]. The trial is based on the hypothesis that MSCs can restore ovarian function. The study is registered but results have not been reported. POF affects approximately 1% of women under 40 and can lead to infertility. This remains an investigational approach.
Mitochondrial-targeted nano-enhancer and MSC spheroids for bone regeneration
In a preclinical study, researchers developed a mitochondrial-targeted nano-enhancer to drive a self-amplifying NAD+ feedback loop and reprogram MSC spheroid metabolism for accelerated bone regeneration [5]. The study focused on the role of mitochondrial oxidative phosphorylation (OXPHOS) in determining MSC fate within three-dimensional spheroids [5]. This is an in vitro and animal model study; no human data are available.
Hair follicle-derived neural crest stem cells and hearing loss
In a rat model of ouabain-induced spiral ganglion neuron (SGN) injury, transplantation of hair follicle-derived neural crest stem cells onto the cochlear nerve surface resulted in partial hearing recovery [6]. The study addressed the challenge of effective cell delivery to the inner ear. This is an animal study; the findings have not been replicated in humans.
Adipose-derived stem cells and erectile dysfunction
In a rat model of cavernous nerve injury, adipose-derived stem cell (ASC) therapy restored erectile function and promoted recruitment of endogenous stem cells [7]. The study investigated the mechanisms underlying the therapeutic effects of exogenous stem cells. This is an animal study; clinical translation is not yet established.
Comparison of stem cell sources in registered trials
| Cell type | Indication | Phase | Status |
|---|---|---|---|
| Mesenchymal stem cells (MSCs) | Non-viral ACLF | Phase II | Ongoing [1] |
| Gene-modified HSPCs | Transfusion-dependent beta-thalassemia | Phase IIb | Ongoing [2] |
| Autologous MSCs | Premature ovarian failure | Not specified | Registered [4] |
| Stem cell therapy (general) | Knee osteoarthritis | Not specified | Under investigation [3] |
Preclinical models of stem cell therapy
| Cell type | Model | Key finding |
|---|---|---|
| MSC spheroids | In vitro / bone regeneration | Mitochondrial-targeted nano-enhancer reprogrammed metabolism [5] |
| Hair follicle-derived neural crest stem cells | Rat SGN injury | Partial hearing recovery [6] |
| Adipose-derived stem cells | Rat cavernous nerve injury | Restored erectile function, recruited endogenous stem cells [7] |
If you are reading this for personal health reasons
The materials and information described here are for laboratory research only. We do not provide dosing, medical guidance, or treatment recommendations. If you are considering any stem cell therapy for yourself, consult a licensed clinician.
Sources
- [1] National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial
- [2] Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia
- [3] The Effect of PEMF for Patients With Knee OA
- [4] "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
- [5] Mitochondrial-targeted nano-enhancer driving a self-amplifying NAD+ feedback loop to reprogram MSC spheroids metabolism for accelerated bone regeneration.
- [6] Partial hearing recovery after cochlear nerve surface transplantation of hair follicle-derived neural crest stem cells in neural hearing loss rat.
- [7] Adipose-derived stem cell therapy restores erectile function and promotes endogenous stem cell recruitment in a rat model of cavernous nerve injury.